The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) Observational Follow-Up Study: Benefits of RAS Blockade With Olmesartan Treatment Are Sustained After Study Discontinuation [Hypertension]
Conclusions
Development of microalbuminuria is a valid marker for future CV events. RAS blockade with Olmesartan might cause sustained reduction (legacy effect) of micro- and macrovascular events.
Source: JAHA:Journal of the American Heart Association - Category: Cardiology Authors: Menne, J., Ritz, E., Ruilope, L. M., Chatzikyrkou, C., Viberti, G., Haller, H. Tags: Hypertension Source Type: research
More News: Benicar | Cardiology | Congestive Heart Failure | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Heart Failure | Hypertension | Men | Study